Progression of glucose-lowering diabetes therapy in TECOS.

ABSTRACT:

Aims

TECOS was a randomized, double-blind, placebo-controlled trial assessing the impact of sitagliptin vs. placebo on cardiovascular outcomes when added to usual care in patients with type 2 diabetes. We report the use of concomitant diabetes medications and the risk for progression to insulin during follow-up.

Materials and methods

TECOS enrolled 14 671 participants with HbA1c 6.5%-8.0% on monotherapy with metformin, pioglitazone, sulfonylurea (SU), or dual therapy with two oral agents or insulin with or without metformin. Subsequent diabetes management was by the participant's usual care physician. Time to initiation of insulin and risk of hypoglycaemia were estimated using Cox proportional hazards models.

Results

The most common glucose-lowering regimens at baseli

SUBMITTER: Bethel MA 

PROVIDER: S-EPMC6354756 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature